Riccardo Alagna

Riccardo Alagna

Auto-generated profile, based on publicly available information

Riccardo Alagna

IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
GMGiovanni Battista Migliori
Giovanni Battista Migliori
STSimon Tiberi
Simon Tiberi
AZAlimuddin Zumla
Alimuddin Zumla
EPEskild Petersen
Eskild Petersen
Chakaya Muhwa JeremiahChakaya Muhwa Jeremiah
Chakaya Muhwa Jeremiah
MNmembers of the Global Tuberculosis Network
members of the Global Tuberculosis Network
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.

20 March 2014 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
LNLuca Norbis
Luca Norbis
RARiccardo Alagna
Riccardo Alagna
ETEnrico Tortoli
Enrico Tortoli
LCLuigi Codecasa
Luigi Codecasa
GMGiovanni Battista Migliori
Giovanni Battista Migliori
DCDaniela M Cirillo
Daniela M Cirillo
Extrapulmonary tuberculosis (EPTB) accounts for a significant proportion of tuberculosis cases worldwide. Nevertheless, the diagnosis is often delayed or even missed due to insidious clinical presentation and poor performance of diagnostic tests. Culture, the classical gold standard for tuberculosis, suffers from increased technical and logistical constraints in EPTB cases. In this review the authors outline current diagnostic options for the main forms of EPTB. The authors also discuss the opportunities and challenges linked in particular to microbiological diagnostics and to the attempts to find a new gold standard test for EPTB. Finally, new biomarkers and tests currently under evaluation are hopefully on the way to introduce significant improvements in EPTB diagnosis, for which clinical suspicion will nevertheless be essential.

2 April 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
RARiccardo Alagna
Riccardo Alagna
GBGiorgio Besozzi
Giorgio Besozzi
LCLuigi Codecasa
Luigi Codecasa
AGAndrea Gori
Andrea Gori
GMGiovanni Battista Migliori
Giovanni Battista Migliori
DCDaniela Cirillo
Daniela Cirillo
March 24th, the tuberculosis (TB) day, is the global call to raise awareness, celebrate successes and remind the world that TB is still the N°1 killer among the infectious causes of death [1]. TB is preventable and curable disease, and its control is a highly cost-effective health intervention. However, diagnostic delay and inadequate treatment contribute to the severity and mortality of the disease as well as the risk of transmission and development of drug resistance. Despite the fact that TB disproportionately impacts low- and middle- income countries, it does not spare any country in the world including those in the European Union/European Economic Area where more than 4000 of people still die for the disease every year [2]. Moreover, the high number of multidrug-resistant (MDR)-TB cases in some countries of the World Health Organization (WHO) European Region poses a growing public health threat. Despite the sheer numbers, TB has for too long been overshadowed by HIV and malaria, and currently by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 (COVID-19) epidemic.

1 August 2016 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Open access
EAEmmanuel André
Emmanuel André
CIC. Isaacs
C. Isaacs
DAD. Affolabi
D. Affolabi
RAR. Alagna
R. Alagna
DBD. Brockmann
D. Brockmann
CBC. Boehme
C. Boehme
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is increasing dramatically, including in resource-limited countries. Although there has never been as much digital information generated, this data source has not been exploited to its full potential. In this opinion paper, we discuss lessons learned from the global scale-up of these laboratory devices and the pathway to tapping the potential of laboratory-generated information in the field of TB by using connectivity. Responding to the demand for connectivity, innovative third-party players have proposed solutions that have been widely adopted by field users of the Xpert® MTB/RIF assay. The experience associated with the utilisation of these systems, which facilitate the monitoring of wide laboratory networks, stressed the need for a more global and comprehensive approach to diagnostic connectivity. In addition to facilitating the reporting of test results, the mobility of digital information allows the sharing of information generated in programme settings. When they become easily accessible, these data can be used to improve patient care, disease surveillance and drug discovery. They should therefore be considered as a public health good. We list several examples of concrete initiatives that should allow data sources to be combined to improve the understanding of the epidemic, support the operational response and, finally, accelerate TB elimination. With the many opportunities that the pooling of data associated with the TB epidemic can provide, pooling of this information at an international level has become an absolute priority.

28 June 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
FGfor StopTB Italia Onlus Group
for StopTB Italia Onlus Group
NRNiccolo Riccardi
Niccolo Riccardi
RARiccardo Alagna
Riccardo Alagna
LSLaura Saderi
Laura Saderi
MFMaurizio Ferrarese
Maurizio Ferrarese
LCLuigi Codecasa
Luigi Codecasa
The increased incidence of drug-resistant TB is a major challenge for effective TB control. Limited therapeutic options and poor treatment outcomes of DR-TB may increase drug-resistance rates. The objective of the study is to retrospectively compare MDR-TB and pre-XDR-TB treatment regimens and outcomes in two large TB reference centres in Italy from January 2000 to January 2015. A retrospective, multicentre study was conducted at the Regional TB Reference Centre Villa Marelli Institute (Milan) and at the Reference Center for MDR-TB and HIV-TB, Eugenio Morelli Hospital (Sondalo). The supra-national Reference Laboratory in Milan performed DST. Inclusion criteria were: age ≥ 18 and culture-confirmed diagnosis of MDR- or pre-XDR TB. Chi-square or Fisher exact test was used to detect differences in the comparison between treatment outcomes, therapeutic regimens, and drug-resistances. Computations were performed with STATA 15. A total of 134 patients were selected. Median (IQR) age at admission was 33 (26–41) years and 90 patients (67.2%) were male. Pulmonary TB was diagnosed in 124 (92.5%) patients. MDR- and pre-XDR-TB cases were 91 (67.9%) and 43 (32.1%), respectively. The WHO shorter MDR-TB regimen could have been prescribed in 16/84 (19.1%) patients. Treatment success was not statistically different between MDR- and pre-XDR-TB (81.3% VS. 81.4%; P = 0.99). Mortality in MDR-TB and pre-XDR-TB groups was 4.4 and 9.3%, respectively (P = 0.2). Median duration of treatment was 18 months and a total of 110 different regimens were administered. Exposure to linezolid, meropenem, and amikacin was associated with a better outcome in both groups (P = 0.001, P < 0.001, and P = 0.004, respectively). Tailored treatment regimens based on DST results can achieve successful outcomes in patients with pre-XDR-TB.

31 March 2013
Verified
Journal Article
Closed access
LNLuca Norbis
Luca Norbis
PMPaolo Miotto
Paolo Miotto
RARiccardo Alagna
Riccardo Alagna
DCDaniela Cirillo
Daniela Cirillo